Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Biochemistry
|
May 2, 2001
Hypersensitization of tumor cells to glycolytic inhibitors
H Liu, Y P Hu, N Savaraj, et al.
European Journal of Biochemistry
|
March 15, 2001
P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine
F Frézard, E Pereira-Maia, P Quidu, et al.
The Journal of Antibiotics
|
May 1, 1985
Sugar-ring analogs of daunorubicin: 3'-epidaunorubicin, 3'-hydroxy-3',5'-diepidaunorubicin and 3',6'-dihydroxy-3',5'-diepidaunorubicin
T M Cheung, D Horton, W Priebe, et al.
Current Medicinal Chemistry
|
February 15, 2001
Analysis of the effects of daunorubicin and WP631 on transcription
J Portugal, B Martín, A Vaquero, et al.
Biochemical Pharmacology
|
December 8, 2000
Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs
Y Hu, C T Moraes, N Savaraj, et al.
Biochimica Et Biophysica Acta
|
July 9, 1999
Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
C Marbeuf-Gueye, D Ettori, W Priebe, et al.
Molecular Pharmacology
|
May 1, 1996
Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells
Y H Ling, A K el-Naggar, W Priebe, et al.
International Journal of Cancer
|
July 1, 1994
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance
E Solary, Y H Ling, R Perez-Soler, et al.
Biochemical and Biophysical Research Communications
|
July 2, 1998
Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump
W Priebe, M Krawczyk, M T Kuo, et al.
European Journal of Medicinal Chemistry
|
August 13, 2019
Curcumin as tyrosine kinase inhibitor in cancer treatment
A Golonko, H Lewandowska, R Świsłocka, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Biochemistry
|
May 2, 2001
Hypersensitization of tumor cells to glycolytic inhibitors
H Liu, Y P Hu, N Savaraj, et al.
European Journal of Biochemistry
|
March 15, 2001
P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine
F Frézard, E Pereira-Maia, P Quidu, et al.
The Journal of Antibiotics
|
May 1, 1985
Sugar-ring analogs of daunorubicin: 3'-epidaunorubicin, 3'-hydroxy-3',5'-diepidaunorubicin and 3',6'-dihydroxy-3',5'-diepidaunorubicin
T M Cheung, D Horton, W Priebe, et al.
Current Medicinal Chemistry
|
February 15, 2001
Analysis of the effects of daunorubicin and WP631 on transcription
J Portugal, B Martín, A Vaquero, et al.
Biochemical Pharmacology
|
December 8, 2000
Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs
Y Hu, C T Moraes, N Savaraj, et al.
Biochimica Et Biophysica Acta
|
July 9, 1999
Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein
C Marbeuf-Gueye, D Ettori, W Priebe, et al.
Molecular Pharmacology
|
May 1, 1996
Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells
Y H Ling, A K el-Naggar, W Priebe, et al.
International Journal of Cancer
|
July 1, 1994
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance
E Solary, Y H Ling, R Perez-Soler, et al.
Biochemical and Biophysical Research Communications
|
July 2, 1998
Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump
W Priebe, M Krawczyk, M T Kuo, et al.
European Journal of Medicinal Chemistry
|
August 13, 2019
Curcumin as tyrosine kinase inhibitor in cancer treatment
A Golonko, H Lewandowska, R Świsłocka, et al.
Page
of 9